Further, through gene expression profiling studies of diabetic mesenteric vasculature, it was demonstrated that EGFR1/ErbB1/HER1 inhibition could normalize approximately 90% of the transcriptomic changes that occurred during the development of diabetes-induced vascular abnormalities (Benter et al., 2009). This evidence concerns the gene EGFR and diabetes mellitus.